TCT 2020 | Our Next Goal Should Be Using IVUS Guidance in Every Angioplasty

The benefits of intravascular ultrasound (IVUS) guidance in all angioplasties with second-generation drug-eluting stents (DES) persist through 3 years of follow-up. These data derive from the extended follow-up of the ULTIMATE study, presented virtually at TCT 2020 and published simultaneously in JACC Intv.

TCT 2020 | Guiar con IVUS todas las angioplastias debería ser nuestro próximo objetivo

At 3 years, target-vessel failure remained lower in patients whose angioplasty was guided by IVUS versus unguided angiography (6.6% vs. 10.7%; p = 0.01). This difference was mainly driven by a significant reduction in clinically-driven revascularization (4.5% vs. 6.9%; p = 0.05).

The advantage provided by IVUS guidance was even better when criteria for an optimal procedural result were met (plaque volume <50%, successful expansion, and lack of dissections).

Both the ULTIMATE and the IVUS-XPL (presented at TCT 2019 and also published in JACC Intv.) studies confirm the clinical benefits of IVUS-guided DES angioplasty.


Read also: TCT 2020 | TAVR Appears to Be the Solution for All Dysfunctional Biological Valves.


The ULTIMATE study, conducted at 8 Chinese sites, enrolled 1448 patients who had silent ischemia, stable or unstable angina, or acute infarction (the latter with over 24 hours between index chest pain and procedure). Of all patients, 78.5% presented acute coronary syndrome, 54.9% presented multivessel lesion, and 30.6% had diabetes. Patients in the IVUS arm received, on average, larger-diameter stents and much more frequently post-dilation with non-compliant balloons of larger diameter and at higher atmospheres.

Criteria for an optimal result were: minimum lumen area of the stent segment >5.0 mm2 or 90% of the minimum lumen area at the distal reference segments; plaque burden at 5 mm proximal or distal to stent edge <50%, and no edge dissection involving media with a length >3 mm.

The safety endpoint was definite or probable stent thrombosis, which was observed in 1 patient in the IVUS arm vs. 8 patients in the angiography arm (0.1% vs. 1.1%; p = 0.02).


Read also: TCT 2020 | Initial Studies Show Incredible Results with Lithotripsy in Calcified Lesions.


This research shows that IVUS guidance can improve angioplasty, reducing the need for repeat revascularization and stent thrombosis events.

Original title: Three-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation.

Reference: Xiao-Fei Gao et al. JACC: Cardiovascular Interventions, article in press. DOI: 10.1016/j.jcin.2020.10.001 y presentado simultáneamente en el congreso TCT 2020 virtual.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...